The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis

Efficacy of canakinumab in mild or severe COVID‐19 pneumonia

(2021) Falasca Katia et al.   Immunity Inflammation and Disease

Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19

(2021) Roberto Caricchio et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis

(2021) Ling Zuo et al.   JOURNAL OF INFECTION

Longitudinal analyses reveal immunological misfiring in severe COVID-19

(2020) Carolina Lucas et al.   NATURE

Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)

(2020) Calvin C Sheng et al.   CLINICAL CARDIOLOGY

Canakinumab as treatment for COVID-19-related pneumonia: a prospective case-control study

(2020) Daniele Generali et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Sixty-Day Mortality Among 520 Italian Hospitalized COVID-19 Patients According to the Adopted Ventilatory Strategy in the Context of an Integrated Multidisciplinary Clinical Organization: A Population-Based Cohort Study

(2020) Antonella Potalivo et al.   Clinical Epidemiology

Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters

(2018) Marco Del Giudice et al.   BRAIN BEHAVIOR AND IMMUNITY

Canakinumab for secondary prevention of atherosclerotic disease

(2017) Davide Capodanno et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Systemic Inflammation Predicts All-Cause Mortality: A Glasgow Inflammation Outcome Study

(2015) Michael J. Proctor et al.   PLoS One

Canakinumab

(2010) Eugen Dhimolea   mAbs